Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

116.04
+0.60000.52%
Post-market: 115.90-0.1400-0.12%19:53 EST
Volume:7.71M
Turnover:892.42M
Market Cap:144.51B
PE:305.37
High:116.31
Open:115.46
Low:114.61
Close:115.44
Loading ...

BRIEF-U.S. FDA Accepts Gilead’S New Drug Applications For Twice-Yearly Lenacapavir For Hiv Prevention Under Priority Review

Reuters
·
18 Feb

Gilead Sciences Says New Drug Application for Lenacapavir to Prevent HIV Accepted by FDA

MT Newswires Live
·
18 Feb

Gilead Sciences Inc - FDA to Review Lenacapavir Nda Under Priority Review, Pdufa Date June 19, 2025

THOMSON REUTERS
·
18 Feb

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for Hiv Prevention Under Priority Review

THOMSON REUTERS
·
18 Feb

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

Zacks
·
18 Feb

Redburn Atlantic Adjusts Price Target on Gilead Sciences to $126 From $125, Maintains Buy Rating

MT Newswires Live
·
18 Feb

Gilead : Deutsche Bank Raises to Buy From Hold

THOMSON REUTERS
·
18 Feb

Arcus Biosciences Inc - Reports $992 Million in Cash and Equivalents

THOMSON REUTERS
·
18 Feb

Arcus Biosciences Inc - Gilead's Exclusive Option to Casdatifan Program Expired

THOMSON REUTERS
·
18 Feb

Arcus Biosciences Inc - Retains Full Global Rights to Casdatifan

THOMSON REUTERS
·
18 Feb

Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?

Zacks
·
18 Feb

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

Zacks
·
17 Feb

Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?

Zacks
·
17 Feb

Gilead Sciences, Inc. (GILD): A Bull Case Theory

Insider Monkey
·
17 Feb

Buy Recommendation for Gilead Sciences: Promising Outlook with Seladelpar Approval and Robust Drug Portfolio

TIPRANKS
·
17 Feb

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Simply Wall St.
·
15 Feb